ArticleHemaSphere2024

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Andrew D Zelenetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.